Get started
Keyword

BCR-ABL1

Description: An oncogenic fusion gene formed by chromosomal rearrangement, encoding an abnormal tyrosine kinase associated with leukemia.
Wikidata ID: wiki/Q27653851
OpenAlex ID: keywords/bcr-abl1
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
2020 · A. Hochhaus, M. Baccarani, et al. · Leukemia · 1,537
PDF
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
2008 · Charles G. Mullighan, Christopher B. Miller, et al. · Nature · 1,074
Transcriptome sequencing to detect gene fusions in cancer
2009 · Christopher A. Maher, Chandan Kumar-Sinha, et al. · Nature · 900
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
2009 · Chen Zhao, Alan Chen, et al. · Nature · 869
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
2018 · Susanne Saussele, Johan Richter, et al. · The Lancet Oncology · 618
PDF
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
2017 · Andrew A. Wylie, Joseph Schoepfer, et al. · Nature · 614
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
2017 · Lars Bullinger, Konstanze Döhner, et al. · Journal of Clinical Oncology · 541
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
2017 · Jorge E. Cortes, Carlo Gambacorti-Passerini, et al. · Journal of Clinical Oncology · 495
Response and Resistance to BCR-ABL1-Targeted Therapies
2020 · Theodore P. Braun, Christopher A. Eide, et al. · Cancer Cell · 483
PDF
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
2019 · Timothy P. Hughes, Michael J. Mauro, et al. · New England Journal of Medicine · 471
PDF
Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression
2016 · María J. Bueno, Ignacio Pérez de Castro, et al. · Cancer Cell · 467
PDF
Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells
2011 · Faiyaz Notta, Charles G. Mullighan, et al. · Nature · 463
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
2018 · Joseph Schoepfer, Wolfgang Jahnke, et al. · Journal of Medicinal Chemistry · 454
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
2015 · Javid J. Moslehi, Michael Deininger · Journal of Clinical Oncology · 443
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
2000 · Claudia S. Huettner, Pu Zhang, et al. · Nature Genetics · 413
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
2004 · Yiguo Hu, Yuhua Liu, et al. · Nature Genetics · 405
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
2010 · Michael G Kharas, Christopher J Lengner, et al. · Nature Medicine · 379
PDF
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
2014 · Matthew S. Zabriskie, Christopher A. Eide, et al. · Cancer Cell · 363
PDF
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
2020 · David Vetrie, G. Vignir Helgason, et al. · Nature reviews. Cancer · 349
PDF
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
2010 · John Colicelli · Science Signaling · 347
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
2021 · Delphine Réa, Michael J. Mauro, et al. · Blood · 342
PDF
Chimeric transcript discovery by paired-end transcriptome sequencing
2009 · Christopher A. Maher, Nallasivam Palanisamy, et al. · Proceedings of the National Academy of Sciences · 337
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
2005 · Anders Castor, Lars Nilsson, et al. · Nature Medicine · 334
IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report
2009 · Giovanni Martinelli, Ilaria Iacobucci, et al. · Journal of Clinical Oncology · 317
The chronic myeloid leukemia stem cell: stemming the tide of persistence
2017 · Tessa L. Holyoake, David Vetrie · Blood · 314
Works count: 4,447
Citation count: 57,720
Year
Topic
Type